Opportunity ID: 333205
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | W81XWH-21-MBRP-IDA |
Funding Opportunity Title: | DoD Military Burn, Idea Development Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 4 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Apr 29, 2021 |
Last Updated Date: | Apr 29, 2021 |
Original Closing Date for Applications: | Sep 30, 2021 |
Current Closing Date for Applications: | Sep 30, 2021 |
Archive Date: | Oct 30, 2021 |
Estimated Total Program Funding: | $2,400,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The intent of the FY21 MBRP IDA is to support new ideas that represent innovative approaches to military-relevant burn research and have the potential to make an important contribution to the MBRP mission. Research deemed innovative may represent a new paradigm, challenge current paradigms, or look at existing problems from new perspectives. Applications proposing applied research and/or preclinical research will be considered for funding. Fundamental basic research and clinical research will not be considered for funding. Impact is a key component of this award mechanism. The potential impact of the research, both short-term and long-term, in addressing the FY21 MBRP Focus Area should be clearly described. High-impact research will, if successful, significantly advance the burn research field and/or the care of burn-injured patients. Burn care interventions or projects scalable to mass casualty events are of particular interest to the MBRP. To be competitive the application must include a sound scientific rationale, logical reasoning, and a well-formulated, testable hypothesis. Inclusion of preliminary and/or published data relevant to the proposed research is required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique data and research resources that the partners bring to the research effort, ultimately advancing burn research which is of significance to the Service Member, military families, and the American public. The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process. The anticipated total costs budgeted for the entire period of performance for an FY21 MBRP IDA will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards will be made no later than September 30, 2022. For additional information refer to Section II.F.1, Federal Award Notices. The CDMRP expects to allot approximately $2.4M to fund approximately four MBRP IDA applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027 Clinical Research Studies and/or Clinical Trials are not allowed and will not be considered. A clinical research study is defined as: (1) patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies; (2) epidemiologic and behavioral studies; and (3) outcomes research and health services research. Note: Studies that meet the requirements for Institutional Review Board (IRB) Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Investigators seeking support to conduct clinical research or early-phase clinical trials should consider the FY21 MBRP Clinical Translational Research Award Program Announcement. Research Involving Human Anatomical Substances: All DOD-funded research involving new and ongoing research with human anatomical substances must be reviewed and approved by the U.S. Army Medical Research and Development Command (USAMRDC) Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow a minimum of 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information. Research Involving Animals: All DOD-funded research involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions, Appendix 1, for additional information. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191 (www.nature.com/nature/journal/ v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.elsevier.com/__data/promis_misc/622936arrive_ guidelines.pdf Use of DOD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for submission requirements. Refer to the General Application Instructions, Appendix 1, Section C for additional detailed information. Encouraged DOD and/or VA Collaboration and Alignment: Military relevance is a key feature of this award. Therefore, PIs are encouraged to collaborate, integrate, and/or align their projects with military and/or VA research laboratories and programs. Although not a comprehensive list, Appendix 2 contains a list of websites which may be useful in identifying information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration. The CDMRP intends that information, data, and research resources generated under awards funded by this program announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: Help@eBRAP.org Email:Help@eBRAP.org |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Packages
Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: Help@eBRAP.org Email: Help@eBRAP.org |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
12.420 | PKG00266813 | Apr 29, 2021 | Sep 30, 2021 | View |